Compare GLU & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLU | VTGN |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.7M | 10.8M |
| IPO Year | N/A | 2014 |
| Metric | GLU | VTGN |
|---|---|---|
| Price | $18.63 | $0.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | 6.6K | ★ 569.7K |
| Earning Date | 01-01-0001 | 06-16-2026 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | $30.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.68 | $0.20 |
| 52 Week High | $21.69 | $5.14 |
| Indicator | GLU | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.96 | 46.52 |
| Support Level | $18.38 | $0.23 |
| Resistance Level | $19.65 | $0.32 |
| Average True Range (ATR) | 0.21 | 0.01 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 0.00 | 49.49 |
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.